FTC Ruling Against Schering-Plough Seen Curtailing Settlement Terms

Law360, New York (December 18, 2003, 12:00 AM EST) -- In a case likely to have far-reaching implications for settlements of patent litigation in the pharmaceutical industry, the U.S. Federal Trade Commission ruled Thursday that three drug makers colluded to keep generic versions of a heart medicine off the market.

Drug makers Schering-Plough, Upsher-Smith Laboratories and American Home Products (now called Wyeth) entered into illegal agreements to keep generic versions of K-Dur off the market, the agency ruled on Thursday.

In acts that amounted to unfair competition, Schering-Plough and its potential generic competitors, Upsher and AHP,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.